Clinical Pharmacokinetics-II [dosing of drugs, tdm]
-
Upload
aimst-university-malaysia -
Category
Education
-
view
895 -
download
0
Transcript of Clinical Pharmacokinetics-II [dosing of drugs, tdm]
![Page 1: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/1.jpg)
DR. BADAR UDDINUMAR
![Page 2: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/2.jpg)
To discuss dosing schedules of drugs
based on pharmacokinetic principles
To discuss therapeutic drug
monitoring
![Page 3: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/3.jpg)
Effective dose: It is the amount of
drug which will produce specific
intensity of effect i.e.; either to treat
the disease or prevent the disease
successfully
![Page 4: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/4.jpg)
Median effective dose (ED50): It is the amount of a drug which produces the desired therapeutic effect in 50% of experimental animals
OR It is the dose of a drug required to produce
a specific intensity of effect in 50% of individuals
It is measure of effectiveness of a drug
![Page 5: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/5.jpg)
Lethal dose: It is the amount of a drug
which will kill certain percentage of
experimental animals to whom the drug is
administered
Fatal dose: When lethal dose reaches
100% or LD100 is known as fatal dose
![Page 6: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/6.jpg)
Median lethal dose (LD50): It is the
amount of a drug which is fatal to 50%
of the experimental animals [i.e.; which kills 50% of the experimental
animals]
It is the measure of acute toxicity of
drugs
![Page 7: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/7.jpg)
Initial loading dose: In some
conditions certain drugs are given in
large doses in the beginning to
obtain an effective blood level
rapidly, this is known as initial
loading dose
![Page 8: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/8.jpg)
Maintenance dose: After achieving
a desired blood level by initial loading
dose, smaller quantity of drug is then
required to maintain the blood level,
this is known as maintenance dose
![Page 9: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/9.jpg)
e.g. initial loading dose of sparfloxacin
is 400 mg. on the first day then
maintenance dose is 200 mg / day as
single daily dose Initial loading dose of digoxin is 1-1.5
mg the maintained at 0.25 mg once or
twice daily dose
![Page 10: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/10.jpg)
Loading Dose
Dose = Cp(Target) x VdDose = Cp(Target) x Vd
![Page 11: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/11.jpg)
What is the loading dose required for drug A if;
Target concentration is 10 mg/L Vd is 0.75 L/kg Patients weight is 75 kg
Answer is on the next slide
![Page 12: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/12.jpg)
Dose = Target Concentration x VD
Vd = 0.75 L/kg x 75 kg = 56.25 L
Target Conc. = 10 mg/L Dose = 10 mg/L x 56.25 L = 565 mg This would probably be rounded to 560 or
even 500 mg
![Page 13: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/13.jpg)
Maintenance Dose = CL x CpSSav
CpSSav is the target average steady state drug concentration
The units of CL are in L/hr or L/hr/kg
Maintenance dose will be in mg/hr so for total daily dose will need multiplying by 24
![Page 14: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/14.jpg)
What maintenance dose is required for drug A if;
Target average SS concentration is 10 mg/L
CL of drug A is 0.015 L/kg/hr
Patient weighs 75 kg
Answer on next slide
![Page 15: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/15.jpg)
Maintenance Dose = CL x CpSSav
CL = 0.015 L/hr/kg x 75 = 1.125 L/hr
Dose = 1.125 L/hr x 10 mg/L = 11.25 mg/hr
So will need 11.25 x 24 mg per day = 270 mg
![Page 16: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/16.jpg)
![Page 17: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/17.jpg)
Effective Dose50 [ED50]
Toxic Dose50 [TD50]
Therapeutic Index
Therapeutic window
![Page 18: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/18.jpg)
![Page 19: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/19.jpg)
![Page 20: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/20.jpg)
Not all people respond to a similar dose
of a drug in the exact same manner
This variability is based upon individual
differences and is associated with toxicity
![Page 21: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/21.jpg)
DrugTherapeutic Concentration Range
Aminoglycoside (gentamicin, tobramycin)
0.5 < - > 8 mg/L
Digoxin 0.5 < - > 8 2.0 ug/L
Phenytoin 10 < - > 8 20 mg/L
Theophylline 10 < - > 8 20 mg/L
![Page 22: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/22.jpg)
This variability is thought to be caused by:
•Pharmacokinetic factors contribute to differing concentrations of the drug at the target area
•Pharmacodynamic factors contribute to differing physiological responses to the same drug concentration -
•Unusual, idiosyncratic, genetically determined or allergic, immunologically sensitized responses
![Page 23: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/23.jpg)
![Page 24: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/24.jpg)
![Page 25: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/25.jpg)
The therapeutic index (also known as therapeutic ratio), is a comparison (ratio) of the amount of a drug that causes the therapeutic effect to the amount that causes death
Quantitatively, it is the ratio of median lethal dose to median effective dose
It is an approximate assessment of the safety of the drugs
![Page 26: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/26.jpg)
A high therapeutic
index is preferable
to a low one
This corresponds to a
situation in which one
would have to take a
much higher dose of a
drug to reach the
lethal threshold than
the dose taken to elicit
the therapeutic effect
![Page 27: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/27.jpg)
Larger the TI greater is the relative safety of the drug
For therapeutic use TI of a drug must be more than one
A drug might have different TI depending on its clinical use e.g.; Aspirin used in headache TI is high
Aspirin used in Rheumatoid arthritis TI is very low
![Page 28: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/28.jpg)
Drugs with high
TI:
Penicillin [dose up to
48 lac units]
Diazepam [up to
200 mg at once, LD
is 750 mg]
Drugs with low
TI:
Digitalis [digoxin]
Anticancer drugs
Phenobarbitone
Warfarin
![Page 29: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/29.jpg)
In animal studies, the therapeutic index is usually defined as the ratio of the TD50 to the ED50
The precision, possible in animal experiments may make it useful to estimate the potential benefit of a drug in humans
![Page 30: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/30.jpg)
The therapeutic index of a drug in humans is almost never known with real precision
Drug trials and accumulated clinical experience often reveal a range of usually effective doses and a different (but sometimes overlapping) range of possibly toxic doses
![Page 31: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/31.jpg)
The clinically acceptable risk of toxicity depends critically on the severity of the disease being treated
For example, the dose range that provides relief from an ordinary headache in the great majority of patients should be very much lower than the dose range that produces serious toxicity
![Page 32: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/32.jpg)
However, for treatment of a lethal disease such as Hodgkin's lymphoma, the acceptable difference between therapeutic and toxic doses may be smaller
![Page 33: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/33.jpg)
It is the ratio of the lethal dose to
1% of population to the effective
dose to 99% of the population
(LD1/ED99)
![Page 34: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/34.jpg)
This is a better safety index than the LD50
for drugs that have both desirable and
undesirable effects, because it factors in
the ends of the spectrum where doses
may be necessary to produce a response
in one person but can, at the same dose,
be lethal in another
![Page 35: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/35.jpg)
Useful range of concentration over
which a drug is therapeutically
beneficial
Therapeutic window may vary from
patient to patient
![Page 36: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/36.jpg)
Drugs with narrow therapeutic windows
require smaller and more frequent doses
or a different method of administration
Drugs with slow elimination rates may
rapidly accumulate to toxic levels….can
choose to give one large initial dose,
following only with small doses
![Page 37: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/37.jpg)
![Page 38: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/38.jpg)
Some Principles
![Page 39: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/39.jpg)
An established relationship between
concentration and response or toxicity
A sensitive and specific assay
An assay that is relatively easy to perform
A narrow therapeutic range
A need to enhance response/prevent
toxicity
![Page 40: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/40.jpg)
Lack of therapeutic response
Toxic effects evident
Potential for non-compliance
Variability in relationship of dose and
concentration
Therapeutic/toxic actions not easily
quantified by clinical endpoints
![Page 41: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/41.jpg)
Assuming patient is at steady-state Assuming patient is actually taking the drug
as prescribed Assuming patient is receiving drug as
prescribed Not knowing when the [drug] was measured in
relation to dose administration Assuming the patient is static and that changes
in condition don’t affect clearance
Not considering drug interactions
![Page 42: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/42.jpg)
Invasive: blood, spinal fluid, biopsy Noninvasive: urine, feces, breath,
saliva
Most analytical methods designed for plasma analysis
C-14, H-3
![Page 43: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/43.jpg)
![Page 44: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/44.jpg)
At the end of the lecture the students will be able to-
Explain with examples the principles of dosing schedules of drugs based on pharmacokinetic principles
Explain with examples the clinical significance of therapeutic drug monitoring
![Page 45: Clinical Pharmacokinetics-II [dosing of drugs, tdm]](https://reader035.fdocuments.in/reader035/viewer/2022081504/5563b643d8b42a38198b4e8b/html5/thumbnails/45.jpg)